Northwest Bio halts enrollment for glioblastoma vax PhIII trial; Germany grants €30 million to East African Community for vaccines, health supply chain management;

> Enrollment for Northwest Bio's ($NWBO) Phase III trial of DCVax for glioblastoma has temporarily halted so its investigators can submit new information for regulatory review. Release

> Germany granted €70 million ($79 million) to the East African Community, €30 million ($34 million) of which will fund vaccines and health supply chain management. More

> There hasn't been a poison ivy vaccine since the 1980s, which was discontinued because it didn't meet new FDA efficacy standards. But an allergist in Pennsylvania is working on a new vaccine, made with poison ivy extract and ethanol. Story

> Pakistan launched a new polio vaccine to accelerate its campaign to eradicate the disease by 2016. Report

Suggested Articles

Already developing coronavirus treatments, Takeda struck a licensing deal to manufacture and market Novavax's vaccine candidate in Japan

On the heels of last week's deal for 120 million Pfizer-BioNTech shots, Japan has locked down 120 million more vaccines from AstraZeneca.

The pandemic price could be lowered for larger deals, CEO Stephane Bancel said. Pfizer and BioNTech priced 100M doses at $19.50 each for the U.S.